Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
9D8 VHH CAR-T
- Development stage
- Preclinical
- Lead developer
- Shanghai HRAIN Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
9D8 VHH CAR-T is an experimental chimeric antigen receptor (CAR) T-cell therapy developed by HRAIN Biotechnology for the treatment of CD70-positive malignancies, specifically renal cell carcinoma (RCC). The therapy employs a variable heavy chain-only (VHH) antibody fragment, or nanobody, as the antigen-binding domain. This VHH was selected from an alpaca-immunized library for its specificity to CD70, a member of the tumor necrosis factor superfamily that is highly expressed in various solid and hematopoietic tumors but has limited expression in healthy tissues. Preclinical data presented at ASCO 2023 demonstrated that 9D8 VHH CAR-T cells effectively eliminate CD70-positive tumor cells in vitro and exhibit significant anti-tumor activity in xenograft mouse models.
- Other names
- anti-CD70 VHH CAR-Tanti-CD-70 VHH CAR-Tanti-CD 70 VHH CAR-T
02
Targets
CD70 (Cluster of Differentiation 70)
Beyond the preview
Go deeper on 9D8 VHH CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 9D8 VHH CAR-T.